Search

Search Constraints

You searched for: Author/Creator Westgeest, Hans

Search Results

1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

2. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Issue 6 (5th September 2022)

3. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)